ストックスクリーナーアプリを入手
3.38
0.59%
0.010
Bioatla Inc (BCAB) 最新ニュース
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB - TradingView
TradingKey - TradingKey
BCAB|Bioatla Inc|Price:3.350|Chg%:-0.110 - TradingKey
BCAB|Bioatla Inc|Price:3.550|Chg%:+0.180 - TradingKey
BCAB|Bioatla Inc|Price:3.481|Chg%:+0.091 - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioAtla Company Profile & Introduction - Moomoo
BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026 - Minichart
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Provides OptimismEarnings Miss Streak - DonanımHaber
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline ProgressesBasic EPS Analysis - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock DeclinesTax Rate Impact - dars.gov.et
BioAtla Inc. (BCAB) Surges Nearly 6% as Shares Test Key Resistance LevelStraddle Setup - dars.gov.et
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4%Net Income Trends - DonanımHaber
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
BioAtla: BioAtla, Inc.Reverse Split Option Symbol: BCAB New Symbol: BCAB1 - Moomoo
BioAtla Inc. (BCAB) Jumps Over 7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherEarnings Surprise Report - dars.gov.et
BioAtla (BCAB) Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock AdvancesEarnings Expansion Phase - dars.gov.et
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrowed Loss and Positive Surprise Boost Investor Sentiment - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla Inc. (BCAB) Q4 2025 Earnings: EPS Beat Driven by Lower Operating Loss, Stock DeclinesConsensus Beat Rate - dars.gov.et
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineHigh Estimate Range - dars.gov.et
BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Driven by Operational DisciplineEarnings Whisper Number - newsline.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces HeadwindsProfitability Factor - The Legal Advocate
BCAB Q4 2025 Earnings: EPS Surprise and Pipeline Focus Drive Positive SentimentEarnings Outlook Update - newsline.com
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95Schiff Line - The Legal Advocate
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentRevenue Surprise History - newsline.com
BCABBioAtla Inc Stock Price and Quote - Finviz
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
0.65%
1.25%
大文字化:
|
ボリューム (24 時間):